Business Context and Reporting Period
Company: Laboratory Corporation of America Holdings (LabCorp)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: LabCorp is a leading provider of diagnostic testing services, operating through routine testing, genomic and esoteric testing, and a joint venture in Ontario, Canada. The company reported strong financial performance driven by pricing discipline, a shift toward higher-priced esoteric tests, and expense controls, despite a 0.7% volume reduction due to severe winter weather in Q1 2010.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2010 |
Six Months Ended June 30, 2010 |
Six Months Ended June 30, 2009 |
|---|---|---|---|
| Net Sales | $1,238.4 | $2,432.0 | $2,344.5 |
| Operating Income | $270.5 | $504.7 | $485.2 |
| Net Earnings (Attributable to LabCorp) | $153.7 | $286.4 | $269.2 |
| Diluted EPS | $1.46 | $2.70 | $2.46 |
| Operating Cash Flow | N/A | $448.2 | $391.3 |
| Cash and Equivalents (Balance Sheet) | $103.8 | $103.8 | $148.5 (Dec 31, 2009) |
| Total Debt (Short + Long Term) | $1,322.8 | $1,322.8 | $1,394.4 (Dec 31, 2009) |
Note: Total Debt calculated as Short-term borrowings ($383.4M) + Long-term debt ($939.4M) as of June 30, 2010.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4.2% in Q2 and 3.7% for the six-month period compared to 2009. Growth was driven by a 6.3% increase in revenue per requisition and a strategic shift to higher-margin genomic and esoteric testing, which now represents 24.5% of total volume (up from 22.7% in 2009).
- Volume Trends: Total requisition volume declined 2.0% in Q2 and 2.5% for the six months, primarily due to the loss of two large government contracts in 2009 and severe winter weather in Q1 2010.
- Profitability: Operating income rose 10.5% in Q2 and 4.0% for the six months. Cost of sales as a percentage of sales improved to 56.9% in Q2 (from 57.3% in 2009) due to automation efficiencies.
- Restructuring: The company recorded $9.3 million in restructuring and special charges for the six months ended June 30, 2010, compared to $10.2 million in the prior year period. This included a $6.2 million write-off of abandoned development costs.
- Acquisitions: The company spent approximately $174.9 million on acquisitions during the first six months of 2010, significantly higher than the $7.5 million spent in the same period in 2009.
Guidance, Outlook, and Risks
- Capital Allocation: The company repurchased approximately 3.0 million shares of common stock for $221.7 million during the first six months of 2010. As of June 30, 2010, $100.1 million remained authorized for future repurchases.
- Pension Plan Changes: The company froze service-based credits for its defined benefit retirement plan effective December 31, 2009. Projected pension expense is expected to decrease from $36.6 million in 2009 to $10.4 million in 2010. This is partially offset by increased 401(k) non-elective contributions estimated at $22.5 million for 2010.
- Debt Management: Interest expense decreased 12.3% for the six-month period due to lower average borrowings and the redemption of zero-coupon subordinated notes in 2009. The company remains in compliance with all debt covenants.
- Legal and Regulatory Risks:
- Medicaid Litigation: The company is involved in a qui tam lawsuit in California regarding alleged improper billing to the state Medicaid program. The company successfully moved to dismiss the original complaint, but an amended complaint was filed in December 2009.
- Patent Disputes: An appeal regarding a patent infringement judgment (Competitive Technologies/Metabolite) is pending in the Tenth Circuit. The company does not expect a material adverse effect.
- Regulatory Inquiries: The company is cooperating with subpoenas from state agencies and the U.S. Office of Inspector General regarding billing practices.
- Outlook: Management expects capital expenditures of approximately $135.0 million for the full year 2010, funded by operating cash flows and credit facilities.
Investor Verification Checklist
- Volume vs. Price Mix: Verify the sustainability of revenue growth given the 2.5% decline in total test volume; confirm if pricing power can offset volume headwinds from lost government contracts.
- Acquisition Integration: Assess the integration progress and accretive impact of the $174.9 million in acquisitions made in the first half of 2010.
- Legal Exposure: Monitor the status of the California Medicaid qui tam lawsuit and other regulatory inquiries, as these could result in significant refunds or penalties.
- Debt Structure: Review the terms of the zero-coupon subordinated notes, specifically the conversion option available to holders through September 30, 2010.
- Noncontrolling Interest: Understand the $134.1 million contractual put obligation related to the Ontario joint venture, which exceeds the current noncontrolling interest balance.